Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | July 09, 2018 | July 11, 2018 |
| ESTABLISHMENT LABS HOLDINGS INC.ESTA · Entity 4473 | Director | June 17, 2022 | June 22, 2022 |
| ROCKWELL MEDICAL, INC.RMTI · Entity 7426 | Director | June 06, 2019 | June 10, 2019 |
| TELA Bio, Inc.TELA · Entity 7381 | Director | May 28, 2025 | May 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date July 09, 2018 · Filed July 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $53.65 · Expires 2028-07-09 | Direct | 9,134 |
Reported balance
After 2018-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-09 · Grant · Acquired 9,134 · Balance 9,134 F1: Option grant for joining the Issuer's Board of Directors. Options vest quarterly as to 12.5% of total share amount beginning with the first vesting date on October 9, 2018 and becoming fully vested July 9, 2020 (two years after grant). |
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $53.65 · Expires 2028-07-09 | Direct | 3,916 |
Reported balance
After 2018-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-09 · Grant · Acquired 3,916 · Balance 3,916 F2: Annual option grant for director of Issuer's Board of Directors, pro-rated for joining Board of Directors during annual period. Option vests quarterly with all shares vested June 1, 2019 in conformity with vesting for such annual director grants. |
Filing footnotes · ownership attribution and instrument terms
F1: Option grant for joining the Issuer's Board of Directors. Options vest quarterly as to 12.5% of total share amount beginning with the first vesting date on October 9, 2018 and becoming fully vested July 9, 2020 (two years after grant).
F2: Annual option grant for director of Issuer's Board of Directors, pro-rated for joining Board of Directors during annual period. Option vests quarterly with all shares vested June 1, 2019 in conformity with vesting for such annual director grants.
ESTABLISHMENT LABS HOLDINGS INC.
Report date June 17, 2022 · Filed June 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 45,276 |
Reported balance
After 2022-06-17 transaction · row 1
1 source rowRow 1 · 2022-06-17 · Grant · Acquired 2,345 · Balance 45,276 F1: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 17, 2023 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 17, 2023 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date.
ROCKWELL MEDICAL, INC.
Report date June 06, 2019 · Filed June 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,674 |
Reported balance
After 2019-06-06 transaction · row 1
1 source rowRow 1 · 2019-06-06 · Grant · Acquired 18,674 · Balance 18,674 F1: Restricted stock units vest on June 6, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.15 · Expires 2029-06-06 | Direct | 22,461 |
Reported balance
After 2019-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-06 · Grant · Acquired 22,461 · Balance 22,461 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vest on June 6, 2020.
TELA Bio, Inc.
Report date May 28, 2025 · Filed May 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,470 |
Reported balance
After 2025-05-28 transaction · row 1
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 7,950 · Balance 18,470 F1: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2035-05-28 | Direct | 11,700 |
Reported balance
After 2025-05-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-28 · Grant · Acquired 11,700 · Balance 11,700 F2: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
F2: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2025 Filed May 30, 2025 16:14 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 11,700 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001062993-25-010569 · form4.xml · derivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires 2035-05-28 F2 · derivative.exercise_date: The option vests on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 28, 2025 Filed May 30, 2025 16:14 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 7,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-010569 · form4.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,470 F1 · shares: These restricted stock units vest on the earlier of (a) May 28, 2026, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 17:00 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 6,200 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0001062993-24-012090 · form4.xml · derivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,200 Underlying: Common Stock · 6,200 shares Expires 2034-06-04 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 4, 2025, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 17:00 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-012090 · form4.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,520 F1 · shares: These restricted stock units vest on the earlier of (a) June 4, 2025, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 16:38 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 5,360 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001062993-23-012778 · form4.xml · derivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 5,360 shares Expires 2033-06-01 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 16:38 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-012778 · form4.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,270 F1 · shares: These restricted stock units vest on the earlier of (a) June 1, 2024, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:04 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | GrantCommon Shares | 2,345 | $0.00 | $0.00 |
DisclosureSEC source: 0001688757-22-000068 · wf-form4_165592822769455.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,276 F1 · kind: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. The shares subject to the award vest in full on the earlier of June 17, 2023 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 16:06 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 5,360 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0001062993-22-014128 · form4.xml · derivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,360 Underlying: Common Stock · 5,360 shares Expires 2032-06-01 F2 · derivative.exercise_date: The option vests on the earlier of (a) June 1, 2023, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Peron's continued service through the applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 16:06 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-014128 · form4.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,135 F1 · shares: These restricted stock units vest on the earlier of (a) June 1, 2023, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Peron's continued service through the applicable vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:56 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 10,825 | $0.00 Strike: $13.16 | $0.00 |
DisclosureSEC source: 0001192482-21-000491 · edgar.xml · derivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,825 Underlying: Common Stock · 10,825 shares Expires 2031-06-02 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 2, 2022, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:34 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | GrantStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $78.11 | $0.00 |
DisclosureSEC source: 0001628280-21-011123 · wf-form4_162206127166423.xml · derivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-05-25 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of May 25, 2022 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:39 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 8,806 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000452 · edgar.xml · derivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,806 Underlying: Common Stock · 8,806 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option vests on the earlier of (a) the first anniversary of June 4, 2020, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan), subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 26, 2020 Filed May 27, 2020 20:44 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | GrantStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $18.14 | $0.00 |
DisclosureSEC source: 0001628280-20-008468 · wf-form4_159061226053183.xml · derivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2030-05-26 F2 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of May 26, 2021 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| May 22, 2020 Filed May 27, 2020 20:44 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | PurchaseCommon Shares | 1,165 | $17.83 | $20,774.86 |
DisclosureSEC source: 0001628280-20-008468 · wf-form4_159061226053183.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,931 F1 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $17.78 to $17.8399 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 20:43 UTC | TELA Bio, Inc. TELA · Entity 7381 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001192482-20-000302 · edgar.xml · derivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-04-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments on each monthly anniversary of April 20, 2020, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| September 04, 2019 Filed Oct 15, 2019 23:05 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | PurchaseCommon Shares | 535 | $19.13 | $10,234.55 |
DisclosureSEC source: 0001628280-19-012295 · wf-form4_157118071876235.xml · nonDerivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,766 Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 23:12 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 22,461 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001104659-19-034645 · a4.xml · derivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,461 Underlying: Common Stock · 22,461 shares Expires 2029-06-06 Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 23:12 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantCommon Stock | 18,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-034645 · a4.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,674 F1 · kind: Restricted stock units vest on June 6, 2020. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:38 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | GrantStock Option (Right to buy) · Derivative | 10,000 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001628280-19-007592 · wf-form4_155976709945827.xml · derivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-06-03 F1 · derivative.exercise_date: The shares subject to the option vest in full on the earlier of June 3, 2020 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| May 23, 2019 Filed Oct 15, 2019 23:05 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | PurchaseCommon Shares | 2,300 | $21.81 | $50,163.00 |
DisclosureSEC source: 0001628280-19-012295 · wf-form4_157118071876235.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,231 Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:28 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | ConversionClass C Ordinary Shares · Derivative | 26,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-18-009511 · wf-form4_153237768270748.xml · derivative · entry 3 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 26,232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class A Ordinary Shares automatically converted into Common Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of Common Shares and had no expiration date. F1 · derivative.exercise_date: The Class A Ordinary Shares automatically converted into Common Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of Common Shares and had no expiration date. F1 · derivative.expiration_date: The Class A Ordinary Shares automatically converted into Common Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of Common Shares and had no expiration date. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:28 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | ConversionClass A Ordinary Shares · Derivative | 12,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-18-009511 · wf-form4_153237768270748.xml · derivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 12,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Class A Ordinary Shares automatically converted into Common Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of Common Shares and had no expiration date. F1 · derivative.exercise_date: The Class A Ordinary Shares automatically converted into Common Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of Common Shares and had no expiration date. F1 · derivative.expiration_date: The Class A Ordinary Shares automatically converted into Common Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of Common Shares and had no expiration date. Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 20:28 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | ConversionCommon Shares | 38,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-009511 · wf-form4_153237768270748.xml · nonDerivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Class A Ordinary Shares automatically converted into Common Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of Common Shares and had no expiration date. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:05 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 3,916 | $0.00 Strike: $53.65 | $0.00 |
DisclosureSEC source: 0001179110-18-009630 · edgar.xml · derivative · entry 2 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,916 Underlying: Common Stock · 3,916 shares Expires 2028-07-09 F2 · derivative.exercise_date: Annual option grant for director of Issuer's Board of Directors, pro-rated for joining Board of Directors during annual period. Option vests quarterly with all shares vested June 1, 2019 in conformity with vesting for such annual director grants. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 21:05 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 9,134 | $0.00 Strike: $53.65 | $0.00 |
DisclosureSEC source: 0001179110-18-009630 · edgar.xml · derivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,134 Underlying: Common Stock · 9,134 shares Expires 2028-07-09 F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest quarterly as to 12.5% of total share amount beginning with the first vesting date on October 9, 2018 and becoming fully vested July 9, 2020 (two years after grant). Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 21:56 UTC | ROCKWELL MEDICAL, INC. RMTI · Entity 7426 | GrantStock Option (Right to Buy) · Derivative | 36,281 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001140361-18-014500 · doc1.xml · derivative · entry 1 COLLERAN LISA N · CIK 0001212312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,281 Underlying: Common Stock · 36,281 shares Expires 2028-03-19 F1 · security: The grant of these options is contingent upon shareholder approval of the 2018 Rockwell Medical, Inc. Long Term Incentive Plan (the "2018 Plan") at the Company's 2018 Annual Meeting of Shareholders. If the Company's shareholders do not approve the 2018 Plan, these contingent options are deemed null and void and may not be exercised by the reporting person. F1 · kind: The grant of these options is contingent upon shareholder approval of the 2018 Rockwell Medical, Inc. Long Term Incentive Plan (the "2018 Plan") at the Company's 2018 Annual Meeting of Shareholders. If the Company's shareholders do not approve the 2018 Plan, these contingent options are deemed null and void and may not be exercised by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.